Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVO
Alvotech
$8.79
-3.0%
$9.54
$7.35
$13.70
$2.73B0.11330,311 shs285,194 shs
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$7.72
-3.9%
$6.50
$1.76
$8.72
$715.80M-0.491.45 million shs1.84 million shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$27.84
-2.6%
$30.77
$24.10
$62.53
$2.68B0.33767,621 shs891,936 shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVO
Alvotech
-2.98%-8.53%-1.57%+6.93%-24.87%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-3.86%-5.28%+17.50%+45.11%+274.76%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-2.62%-10.16%-5.43%-17.54%-47.59%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+1.94%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alvotech stock logo
ALVO
Alvotech
3.3792 of 5 stars
3.54.00.00.03.40.01.9
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
2.5111 of 5 stars
4.51.00.00.00.02.50.6
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.3269 of 5 stars
3.40.00.03.72.12.50.0
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVO
Alvotech
3.00
Buy$14.0059.27% Upside
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.00
Buy$11.7552.20% Upside
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.80
Moderate Buy$69.50149.64% Upside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AMLX, CRNX, MOR, and ALVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Alvotech stock logo
ALVO
Alvotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $14.00
7/10/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$10.00
7/10/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$36.00
6/27/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/24/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$17.00
6/17/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
5/30/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/14/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
5/9/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVO
Alvotech
$491.98M5.39N/AN/A($1.37) per share-6.42
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$1.27M-541.01N/AN/A$2.40 per share3.22
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$1.04M2,506.40N/AN/A$14.29 per share1.95
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVO
Alvotech
-$231.86M$0.3723.7643.95N/A16.42%-36.37%12.70%8/21/2025 (Estimated)
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$301.74M-$3.11N/AN/AN/AN/A-77.21%-63.84%8/7/2025 (Confirmed)
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$298.41M-$3.82N/AN/AN/AN/A-30.95%-28.12%8/7/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A

Latest AMLX, CRNX, MOR, and ALVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/21/2025Q2 2025
Alvotech stock logo
ALVO
Alvotech
-$0.06N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.43N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.13N/AN/AN/A$0.52 millionN/A
5/8/2025Q1 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.45-$0.42+$0.03-$0.42N/AN/A
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
5/7/2025Q1 2025
Alvotech stock logo
ALVO
Alvotech
-$0.17$0.35+$0.52$0.35N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVO
Alvotech
N/AN/AN/AN/AN/A
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.0213.16%N/AN/A N/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alvotech stock logo
ALVO
Alvotech
N/A
1.73
1.19
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.05
12.05
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
22.53
22.53
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVO
Alvotech
N/A
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVO
Alvotech
0.46%
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
11.70%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVO
Alvotech
1,032301.48 million300.10 millionNot Optionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.14 million78.71 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million89.32 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable

Recent News About These Companies

Novartis to shut MorphSys sites amid pelabresib delay
Novartis sheds MorphoSys staff, sites after pelabresib delay
Novartis shutters MorphoSys sites, lays off staff
Novartis raises mid-term sales guidance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alvotech stock logo

Alvotech NASDAQ:ALVO

$8.79 -0.27 (-2.98%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.79 0.00 (0.00%)
As of 08/1/2025 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$7.72 -0.31 (-3.86%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.56 -0.16 (-2.07%)
As of 08/1/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$27.84 -0.75 (-2.62%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$27.82 -0.02 (-0.05%)
As of 08/1/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 07/31/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.